Background: Pleomorphic carcinoma of the lung is a malignant epithelial tumor that contains carcinomatous and sarcomatoid components. Due to its rarity, few studies have been reported, and its clinical and pathological characteristics remain unclear.
Introduction
According to the World Health Organization classification of lung tumors, pleomorphic carcinoma of the lung is one of five subgroups of sarcomatoid carcinoma [1] , which itself is defined as a group of poorly differentiated tumors Since its diagnostic criteria were confirmed, pulmonary pleomorphic carcinoma has been diagnosed more frequently. It is essential to understand its clinical behavior for effective management of patients with this disease.
However, as pulmonary pleomorphic carcinoma is rare (only 0.1-0.4% of all malignant tumors of the lung) [2] [3] [4] , its clinical and pathological characteristics are not well known. We have retrospectively investigated 22 patients with pulmonary pleomorphic carcinoma diagnosed by surgical resection, autopsy, or transbronchial biopsy (TBB). Radiological findings, results of positron emission tomography with 18-fluorodeoxy-glucose (FDG-PET), treatment, and clinical course are described in this report.
Material and methods

Patients
We 
CT and FDG-PET protocol
Chest computed tomography (CT) was performed in all patients. The size, location, and internal density of the tumor, and the presence of a cavity were evaluated. Hilar and mediastinal lymph nodes were measured, and if the short-axis diameter of a lymph node was equal to or longer than 10 mm, it was considered positive. Abdomen CT was also performed to detect metastases to abdominal organs such as liver, kidney, and adrenal gland.
Positron emission tomography with 18-fluorodeoxy-glucose (FDG-PET) has been used for evaluating tumors of the lung as well as lymph node and distant metastases. The Standardized Uptake Value (SUV), which was obtained by placing a region of interest over the lesion and dividing the value (in microcuries per cubic centimeter) by the injected dose (in microcuries) divided by the patient's body weight (in grams) [5] , was measured. In this series, 12 patients underwent FDG-PET.
Pathological diagnosis
Pleomorphic carcinoma was defined as non-small cell carcinoma containing at least 10% sarcomatoid components. Pathologists evaluated specimens that were obtained by surgery, autopsy and TBB. In this study, when a TBB specimen contained both carcinomatous and sarcomatoid components, and the non-small cell lung cancer component was clearly distinct from the spindle/giant cell carcinoma, the tumor was diagnosed as pleomorphic carcinoma.
Evaluation of response to chemotherapy or radiotherapy
Response evaluations for chemotherapy and/or radiotherapy were assessed using RECIST (Response Evaluation Criteria in Solid Tumors) guidelines [6] .
Overall survival was defined as the time from the first day of treatment until death from any cause.
Statistical analysis
In this paper, statistical values are given as mean ± standard deviation.
Continuous variables were compared using the Student t test or Mann-Whitney test, as appropriate. All survival curves for time-to-event variables were created using the Kaplan-Meier method [7] .
Results
Patient characteristics
Patient characteristics are summarized in (CA19-9), Sialyl Lewis (x) (SLX), squamous-cell carcinoma antigen (SCC-Ag), pro-gastrin-releasing peptide (Pro-GRP), and neuron-specific enolase (NSE), were specific and useful for diagnosis of pleomorphic carcinoma of the lung.
Radiological findings
Chest CT was performed in all 22 cases and revealed fairly large tumors:
45.3 ± 21.9 mm in diameter (range 14 -110). All tumors were observed as mass or nodule, and ground glass opacity pattern or consolidations were not seen in our study. 
Diagnosis and pathological findings
Fifteen cases of pulmonary pleomorphic carcinoma were diagnosed by surgical resection ( [2] [3] [4] . Since its pathological definition became widely recognized, pleomorphic carcinoma has been diagnosed more frequently: in our study, its frequency was 0.90% (22/2447 cases). In another recent study, it was found to be 1.6% (45/2743) of resected non-small cell lung cancer (NSCLC) [8] . As in previous reports [8] [9] [10] [11] [12] , most cases in our study were male with a history of smoking; they exhibited symptoms such as hemoptysis and cough.
Pleomorphic carcinoma of the lung was often found as a large mass, more than 4 -5 cm in diameter. In our study, the tumors tended to be located in the [13] . There was a statistically significant difference in SUV of T2-4 diseases between NSCLC and pleomorphic carcinoma (P < 0.01), whereas there was no significant difference in SUV of T1 diseases (P = 0.48). Although there were only two T1 tumors in our study, our FDG-PET result suggests that the SUV of pleomorphic carcinoma might be higher than that of common non-small cell lung cancer, which might be helpful in diagnosis.
Biochemical examination revealed serum CEA to be elevated in 63.6% of patients (14 cases). This marker is known to be specific for other tumors including adenocarcinoma and is affected by external factors such as smoking.
SCC, CYFRA, SLX, Pro-GRP, and NSE were considered to be non-specific markers for pulmonary pleomorphic carcinoma.
Distant metastasis was frequently observed in patients with pleomorphic carcinoma of the lung. The major sites of distant metastases were the same as those for other malignant epithelial lung tumors, i.e., bone, brain, lung, liver and adrenal gland, but the progression of this tumor is particularly rapid, and distant metastases seem to strongly influence prognosis. Autopsies revealed that pleomorphic carcinomas of the lung tended to expand into various lesions: minor sites of metastases such as thyroid grand, peritoneum and lymph nodes of abdomen could not be found by clinical examination before death. In particular, metastases to small intestine were revealed by autopsy in two patients, one of whose death (patient 18) was a result of intestine perforation.
Chest wall invasions and mediastinal invasions were commonly observed in the 15 patients who underwent surgical resection, as postoperative pathological findings rather than preoperative prediction. Because of pT3 disease, three cases were given adjuvant therapy (irradiation (patient 7) or chemotherapy (patient 1) or chemo-radiation therapy (patient 6)). commented that advanced pulmonary pleomorphic carcinoma showed poor response to chemotherapy regimens [11] . Of note is the fact that we experienced one partial response to gefitinib despite this being second-line treatment (patient 9). The tumor in this case was diagnosed as pleomorphic carcinoma by surgical resection, and EGFR mutation (L858R) was detected.
The presence of EGFR mutation is related to a patient's background and pathological subtypes of the lung cancer: it influences response to gefitinib [14] . However, the good response to second-line gefitinib highlighted the importance of molecular targeted therapy for this entity.
Conclusion
In conclusion, we retrospectively analyzed 22 cases of pulmonary pleomorphic carcinoma in a total of 2447 cases of primary lung cancer.
Pulmonary pleomorphic carcinoma had strong malignant potential with frequent distant metastases. We demonstrated that surgical treatment and appropriate follow-up therapy including the use of a molecular targeting drug (e.g., gefitinib
for patients with adenocarcinoma as carcinomatous component) might improve outcomes. Some other important findings regarding the characteristics and clinical course of the tumor have been described in this report, and further investigations will be needed to elucidate more definitive clinical features and to establish appropriate methodological strategies for pleomorphic carcinoma of the lung. 
